SCHEMBL14280956

SCHEMBL14280956

CC(=C1CN(S(=O)(=O)c2ccc(Cl)cc2)c2ccccc2C1=O)N(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 3/20 0.59
▸ KCNN4 O15554 2/20 0.59
▸ PSEN1 P49768 3/20 0.50
▸ PSEN2 P49810 3/20 0.50
▸ APH1B Q8WW43 3/20 0.50
▸ NCSTN Q92542 3/20 0.50
▸ APH1A Q96BI3 3/20 0.50
▸ PSENEN Q9NZ42 3/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ MMP2 P08253 1/20 0.45
▸ TSHR P16473 2/20 0.38
▸ CMA1 P23946 2/20 0.38
▸ CTSG P08311 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA3 P07451 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA6 P23280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14280941 0.78 KCNA3 (0.60) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL8232487 0.76 KCNA3 (0.64) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL3041480 0.75 KCNA3 (1.00) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL8135760 0.71 KCNA3 (0.62) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL8135759 0.71 KCNA3 (0.62) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2705507 0.70 KMT2A (0.68) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2702553 0.68 KCNA3 (0.64) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL14502625 0.67 KCNN4 (0.55) KCNA3KCNN4MEN1KMT2AMMP2
SCHEMBL2702617 0.67 PSEN1 (1.00) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2702464 0.67 PSEN1 (0.64) KCNA3KCNN4PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 KCNA3 2000/4885KCNN4 3516/4885PSEN1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback